Virvio

Virvio is a Seattle-based pre-clinical therapeutic biotechnology company. The company focuses on difficult disease targets and designs novel biologics. It has the stated goal of creating products for common conditions and diseases such as asthma and influenza. In the case of the product being developed for influenza, it is intended to be for both pre- and post-exposure containment of viruses. It has created computationally-designed minibinders that resemble monoclonal antibodies. The minibinders are safer and more effective biologic alternatives and Virvio uses them to create products such as pills, inhalers, or creams so that the remedy for common illnesses can be readily available in pharmacies worldwide. The product is being designed so that it can be taken in a single dosage and stockpiled in the case of a global pandemic.

The company has received a grant in February 2016 as a form of funding. It came from the National Institutes of Health and was a reported $209,000.